WGS
GeneDx Holdings Corp.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$85.99
−1.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 454.4M | 427.5M | 305.4M | 202.6M | 234.7M |
| Cost of Revenue | 144.5M | 129.4M | 111.1M | 112.6M | 261.4M |
| Gross Profit | 309.9M | 298.2M | 194.4M | 90.0M | (26.8M) |
| Operating Expenses | |||||
| R&D Expense | 83.3M | 72.0M | 45.7M | 58.3M | 86.2M |
| SG&A Expense | 292.3M | 239.2M | 168.5M | 194.7M | 338.2M |
| General & Admin Expense | 91.0M | 150.8M | 101.1M | 133.8M | 216.2M |
| Selling & Marketing Expense | 50.6M | 88.4M | 67.4M | 61.0M | 122.1M |
| Other Expenses | (5.1M) | — | 3.4M | 17.6M | 216.5M |
| Total Operating Expenses | 370.5M | 311.3M | 217.6M | 270.6M | 640.9M |
| Cost and Expenses | 515.0M | 439.3M | 328.7M | 383.2M | 902.3M |
| Operating Income (EBIT) | (60.6M) | (11.8M) | (23.2M) | (180.6M) | (667.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 1.1M | 2.5M |
| Interest Expense | 3.0M | 2.5M | 3.0M | — | 3.2M |
| Net Interest Income | (3.0M) | (2.5M) | (3.0M) | 1.1M | (666.0K) |
| Other Non-Op Income/Expense | (45.7M) | (9.3M) | (29.4M) | 3.9M | 69.6M |
| Non-Operating Income (excl Interest) | 42.7M | 6.8M | 26.4M | (10.4M) | (210.1M) |
| EBT (Pre-Tax Income) | (106.3M) | (21.1M) | (52.6M) | (176.7M) | (598.0M) |
| Income Tax Expense | 1.1M | (116.0K) | (343.0K) | (926.0K) | (49.1M) |
| Bottom Line | |||||
| Net Income | (106.4M) | (21.0M) | (52.3M) | (175.8M) | (549.0M) |
| Earnings from Cont. Ops | (107.4M) | (21.0M) | (52.3M) | (175.8M) | (549.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (106.4M) | (21.0M) | (52.3M) | (175.8M) | (549.0M) |
| Per Share | |||||
| Basic EPS | ($3.64) | ($0.73) | ($1.94) | ($7.23) | ($53.63) |
| Diluted EPS | ($3.62) | ($0.73) | ($1.94) | ($7.23) | ($53.63) |
| Revenue Per Share | $15.30 | $15.90 | $11.36 | $8.33 | $22.93 |
| Shares | |||||
| Basic Shares Outstanding | 29.7M | 26.9M | 26.9M | 24.3M | 10.2M |
| Diluted Shares Outstanding | 29.7M | 26.9M | 26.9M | 24.3M | 10.2M |
| Profitability Metrics | |||||
| EBITDA | (76.4M) | 6.6M | (27.6M) | (136.5M) | (398.2M) |
| D&A | 26.9M | 25.2M | 22.0M | 33.7M | 59.3M |
| EBIT | (103.3M) | (18.6M) | (49.6M) | (170.2M) | (457.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026